专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5980888A Keratinocytes attached to microcarriers for treatment of skin wounds 失效
标题翻译：附着于微载体上的角质细胞用于治疗皮肤伤口
公开(公告)号：US5980888A
公开(公告)日：1999-11-09
申请号：US809408
申请日：1997-04-23
申请人： Nikolaos Dimoudis , Anton Hartinger
发明人： Nikolaos Dimoudis , Anton Hartinger
IPC分类号： A61L27/60 , C12N5/071 , C12N5/00 , C12N5/06 , C12N11/02 , C12N11/10
CPC分类号： C12N5/0629 , A61L27/60 , C12N2531/00 , C12N2533/54 , C12N2533/70
摘要： Epithelial cells are attached to microcarriers to form a transplantation material for treatment of skin wounds. Preferably, keratinocyte-covered microcarriers are prepared using microcarriers having a diameter of 50 to 500 .mu.m, and obtaining a coverage of keratinocytes of 30 to 100% of the maximum coverage. An optimum coverage is between 50 and 80% and preferably between 60 and 70%. Keratinocytes are selected from autologous cells, allogenic cells and a combination of these cells. The microcarriers may be pre-coated with eukaryotic cells or an extracellular matrix protein such as collagen before keratinocytes are attached. The keratinocyte-covered microcarriers may be combined with a cryoprotective substance for storage at +3.degree. C. to -196.degree. C. prior to use. Keratinocytes are attached to the microcarriers by pre-culturing the keratinocytes, and then culturing the keratinocytes in the presence of the microcarriers while intermittently stirring. A serum free culture medium may be used. Initial culturing in the presence of the microcarriers may be in the smallest amount of medium required to prevent the keratinocytes from dying, and after keratinocyte attachment, adding medium to provide a volume for optimum growth. The keratinocyte-covered microcarriers are applied to a skin wound and the wound is covered with a protective dressing. A pharmaceutical formulation and kit are prepared containing the keratinocyte-covered microcarriers may.
摘要翻译： PCT No.PCT / EP95 / 04164 Sec。 371日期1997年4月23日 102（e）日期1997年4月23日PCT提交1995年10月24日PCT公布。出版物WO96 / 日期1996年5月2日上皮细胞连接到微载体上以形成用于治疗皮肤伤口的移植材料。优选地，使用直径为50至500μm的微载体制备角质形成细胞覆盖的微载体，并获得角膜细胞的覆盖范围为最大覆盖率的30至100％。最佳覆盖率在50-80％之间，优选在60-70％之间。角质形成细胞选自自体细胞，同种异体细胞和这些细胞的组合。微载体可以预先包被真核细胞或细胞外基质蛋白如角质形成细胞附着前的胶原蛋白。角质形成细胞覆盖的微载体可以与冷冻保护物质组合，以在使用前在+ 3℃至-196℃保存。通过预培养角化细胞将角质细胞附着于微载体，然后在间歇性搅拌下在微载体存在下培养角质形成细胞。可以使用无血清培养基。在微载体存在下的初始培养可以是防止角质形成细胞死亡所需的最小量的培养基，并且在角质形成细胞附着后，加入培养基以提供用于最佳生长的体积。将角质形成细胞覆盖的微载体施用于皮肤伤口，并用保护敷料覆盖伤口。制备含有角化细胞覆盖的微载体的药物制剂和试剂盒。

2. 发明授权

US07097854B2 Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds 失效
标题翻译：氨基醇衍生物，其制备方法和药物制剂以及含有这些化合物的试剂
公开(公告)号：US07097854B2
公开(公告)日：2006-08-29
申请号：US10059207
申请日：2002-01-31
申请人： Walter-Gunar Friebe , Nikolaos Dimoudis , Uwe Michaelis , Bernhard Knipp
发明人： Walter-Gunar Friebe , Nikolaos Dimoudis , Uwe Michaelis , Bernhard Knipp
IPC分类号： A61K9/127 , A61K38/00 , A01N43/04
CPC分类号： C07D295/13 , A61K48/00 , C07C219/06 , C07D211/26
摘要： The present invention relates to new amino alcohol derivatives, process for the production thereof and medicaments and reagents containing these compounds.
摘要翻译：本发明涉及新的氨基醇衍生物，其制备方法以及含有这些化合物的药物和试剂。

3. 发明授权

US08859737B2 Anti-HER3 antibodies and uses thereof 有权
标题翻译：抗HER3抗体及其用途
公开(公告)号：US08859737B2
公开(公告)日：2014-10-14
申请号：US12971300
申请日：2010-12-17
申请人： Birgit Bossenmaier , Nikolaos Dimoudis , Thomas Friess , Guy Georges , Irene Kolm , Hans-Willi Krell , Valeria Lifke , Ekkehard Moessner
发明人： Birgit Bossenmaier , Nikolaos Dimoudis , Thomas Friess , Guy Georges , Irene Kolm , Hans-Willi Krell , Valeria Lifke , Ekkehard Moessner
IPC分类号： C12P21/08 , C07K16/32 , A61K39/00
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及与人HER3（抗HER3抗体）结合的抗体，其制备方法，含有所述抗体的药物组合物及其用途。

4. 发明申请

US20050153416A1 Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof 审中-公开
标题翻译：人类明胶酶a和聚乙二醇的c结构域的缀合物，其纯化方法和用途
公开(公告)号：US20050153416A1
公开(公告)日：2005-07-14
申请号：US10505990
申请日：2003-02-28
申请人： Nikolaos Dimoudis , Erhard Kopetzki , Martin Lanzendoerfer , Werner Scheuer
发明人： Nikolaos Dimoudis , Erhard Kopetzki , Martin Lanzendoerfer , Werner Scheuer
IPC分类号： C12N15/09 , A61K38/00 , A61K38/48 , A61K47/48 , A61P35/00 , C12N9/64
CPC分类号： C12N9/6491 , A61K38/4886 , A61K47/60
摘要： There is provided a conjugate comprising the C domain of human gelatinase A (PEX domain, PEX) and one to three poly(ethylene glycol) group(s), said poly(ethylene glycol) group(s) having an overall weight of from about 10 to 40 kDa and being conjugated via primary amino group(s) of said PEX. The conjugates are useful as anticancer agents.
摘要翻译：提供了包含人明胶酶A（PEX结构域，PEX）和一至三个聚（乙二醇）基团的C结构域的共轭物，所述聚（乙二醇）基团的总重量为约 10至40kDa，并通过所述PEX的伯氨基共轭。缀合物可用作抗癌剂。

5. 发明授权

US08999327B2 Antibodies against human CSF-1R and uses thereof 有权
标题翻译：针对人CSF-1R的抗体及其用途
公开(公告)号：US08999327B2
公开(公告)日：2015-04-07
申请号：US12962445
申请日：2010-12-07
申请人： Nikolaos Dimoudis , Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Pickl , Carola Ries , Stefan Seeber , Kerstin Krueger
发明人： Nikolaos Dimoudis , Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Pickl , Carola Ries , Stefan Seeber , Martin Lanzendoerfer
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及针对人CSF-1R（抗CSF-1R抗体）的抗体，其制备方法，含有所述抗体的药物组合物及其用途。

6. 发明授权

US08900581B2 Antibodies against human CSF-1R and uses thereof 有权
公开(公告)号：US08900581B2
公开(公告)日：2014-12-02
申请号：US12962445
申请日：2010-12-07
申请人： Nikolaos Dimoudis , Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Pickl , Carola Ries , Stefan Seeber , Kerstin Krueger
发明人： Nikolaos Dimoudis , Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Pickl , Carola Ries , Stefan Seeber , Martin Lanzendoerfer
IPC分类号： A61K39/395
摘要： The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

7. 发明授权

US08003099B2 Antibodies against human IL17 and uses thereof 有权
标题翻译：针对人IL17的抗体及其用途
公开(公告)号：US08003099B2
公开(公告)日：2011-08-23
申请号：US12586893
申请日：2009-09-29
申请人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
发明人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： C07K16/244 , C07K2317/76 , Y10S530/809
摘要： An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
摘要翻译：结合IL-17的抗体，其特征在于与单克隆抗体3C1结合的相同的IL-17表位结合，并且在铰链区在氨基酸位置216-240，优选在氨基酸位置220-修饰的人IgG1同种型， 240，CH1和CH2之间和/或在CH2和CH3之间的氨基酸位置327-331的第二区域间区域具有治疗炎性疾病的有利性质。

8. 发明申请

US20130195844A1 ANTIBODIES AGAINST HUMAN IL17 AND USES THEREOF 审中-公开
标题翻译：抗体人类IL17抗体及其用途
公开(公告)号：US20130195844A1
公开(公告)日：2013-08-01
申请号：US13186109
申请日：2011-07-19
申请人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
发明人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
IPC分类号： C07K16/24
CPC分类号： C07K16/244 , C07K2317/76 , Y10S530/809
摘要： An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
摘要翻译：结合IL-17的抗体，其特征在于与单克隆抗体3C1结合的相同的IL-17表位结合，并且在氨基酸位置216-240，优选氨基酸位置220-位于铰链区修饰的人IgG1同种型， 240，CH1和CH2之间和/或在CH2和CH3之间的氨基酸位置327-331的第二区域间区域具有治疗炎性疾病的有利性质。

9. 发明申请

US20110171222A1 ANTI-HER3 ANTIBODIES AND USES THEREOF 有权
标题翻译：抗HER3抗体及其用途
公开(公告)号：US20110171222A1
公开(公告)日：2011-07-14
申请号：US12971300
申请日：2010-12-17
申请人： Birgit Bossenmaier , Nikolaos Dimoudis , Thomas Friess , Guy Georges , Irene Kolm , Hans-Willi Krell , Valeria Lifke , Ekkehard Moessner
发明人： Birgit Bossenmaier , Nikolaos Dimoudis , Thomas Friess , Guy Georges , Irene Kolm , Hans-Willi Krell , Valeria Lifke , Ekkehard Moessner
IPC分类号： A61K39/395 , C07K16/32 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/00 , C12P21/02 , A61P35/00
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/40 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及与人HER3（抗HER3抗体）结合的抗体，其制备方法，含有所述抗体的药物组合物及其用途。

10. 发明申请

US20100080812A1 Antibodies against human IL17 and uses thereof 有权
标题翻译：针对人IL17的抗体及其用途
公开(公告)号：US20100080812A1
公开(公告)日：2010-04-01
申请号：US12586893
申请日：2009-09-29
申请人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
发明人： Johannes Auer , Nikolaos Dimoudis , Guy Georges , Petra Hanke , Hendrik Knoetgen , Ekkehard Moessner , Claire Louise Langrish
IPC分类号： A61K39/395 , C07K16/00 , C07H21/00 , A61P11/06 , A61P19/02 , C12N15/63 , C12P21/00 , C12N5/00
CPC分类号： C07K16/244 , C07K2317/76 , Y10S530/809
摘要： An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
摘要翻译：结合IL-17的抗体，其特征在于与单克隆抗体3C1结合的相同的IL-17表位结合，并且在氨基酸位置216-240，优选氨基酸位置220-位于铰链区修饰的人IgG1同种型， 240，CH1和CH2之间和/或在CH2和CH3之间的氨基酸位置327-331的第二区域间区域具有治疗炎性疾病的有利性质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式